Role of PD-L1 and PD-L2 in allergic diseases and asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 2, 2011, Pages 155-162

  Singh, A K ^a   Stock, P ^b   Akbari, O ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

asthma; programmed death ligand 1; programmed death ligand 2; programmed death 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR;

ALLERGIC ASTHMA; BRONCHUS HYPERREACTIVITY; CD4+ T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD80; ASTHMA; HUMANS; HYPERSENSITIVITY; LIGANDS;

EID: 78651071600     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02458.x     Document Type: Review

References (84)

1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A,. Is the prevalence of asthma declining? Systematic review of epidemiological studies Allergy 2010; 65: 152-167.
2. Galli SJ, Tsai M, Piliponsky AM,. The development of allergic inflammation. Nature 2008; 454: 445-454.
3. von Garnier C, Wikstrom ME, Zosky G, Turner DJ, Sly PD, Smith M, et al. Allergic airways disease develops after an increase in allergen capture and processing in the airway mucosa. J Immunol 2007; 179: 5748-5759.
4. Busse WW, Lemanske RF Jr,. Asthma. N Engl J Med 2001; 344: 350-362.
5. Kiley J, Smith R, Noel P,. Asthma phenotypes. Curr Opin Pulm Med 2007; 13: 19-23.
6. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH,. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002; 3: 715-720.
7. Brusasco V, Crimi E, Pellegrino R,. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax 1998; 53: 992-998. (Pubitemid 28494343)
8. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9: 582-588.
9. Lloyd CM, Hawrylowicz CM,. Regulatory T cells in asthma. Immunity 2009; 31: 438-449.
10. Stock P, Akbari O, Berry G, Freeman GJ, Dekruyff RH, Umetsu DT,. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol 2004; 5: 1149-1156.
11. Lafferty KJ, Cooley MA, Woolnough J, Walker KZ,. Thyroid allograft immunogenicity is reduced after a period in organ culture. Science 1975; 188: 259-261.
12. Croft M,. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3: 609-620.
13. Keir ME, Butte MJ, Freeman GJ, Sharpe AH,. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
14. Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol 2007; 179: 7466-7477.
15. Schreiner B, Bailey SL, Shin T, Chen L, Miller SD,. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol 2008; 38: 2706-2717.
16. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T,. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005; 102: 11823-11828.
17. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
18. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
19. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T,. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003; 198: 39-50.
20. Liang SC, Greenwald RJ, Latchman YE, Rosas L, Satoskar A, Freeman GJ, et al. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol 2006; 36: 58-64.
21. Terrazas LI, Montero D, Terrazas CA, Reyes JL, Rodriguez-Sosa M,. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int J Parasitol 2005; 35: 1349-1358.
22. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398-11403.
23. Velu V, Kannanganat S, Ibegbu C, Chennareddi L, Villinger F, Freeman GJ, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007; 81: 5819-5828.
24. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
25. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
26. Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006; 177: 5928-5935.
27. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174: 6648-6656.
28. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 2010; 3: 81-91.
29. Ishida Y, Agata Y, Shibahara K, Honjo T,. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
30. Nishimura H, Nose M, Hiai H, Minato N, Honjo T,. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
31. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R,. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 2003; 48: 174-185.
32. Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003; 30: 1410-1419.
33. Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005; 32: 2156-2163.
34. Okazaki T, Honjo T,. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824.
35. Dong H, Zhu G, Tamada K, Chen L,. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
36. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
37. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
38. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846.
39. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
40. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003; 33: 3117-3126.
41. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545.
42. Loke P, Allison JP,. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5336-5341.
43. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007; 109: 1499-1505.
44. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S,. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007; 56: 1173-1182.
45. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157.
46. Zhang P, Su DM, Liang M, Fu J,. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008; 45: 1470-1476.
47. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M,. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094-5100.
48. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-17179.
49. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N,. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
50. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505.
51. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-69.
52. Maier LM, Wicker LS,. Genetic susceptibility to type 1 diabetes. Curr Opin Immunol 2005; 17: 601-608.
53. Anderson MS, Bluestone JA,. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-485.
54. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
55. Matsumoto K, Fukuyama S, Eguchi-Tsuda M, Nakano T, Matsumoto T, Matsumura M, et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun 2008; 365: 170-175.
56. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol 2004; 172: 2530-2541.
57. Oflazoglu E, Swart DA, Anders-Bartholo P, Jessup HK, Norment AM, Lawrence WA, et al. Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. Eur J Immunol 2004; 34: 3326-3336.
58. Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ,. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol 2004; 230: 89-98.
59. Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci USA 2006; 103: 11695-11700.
60. Shortman K, Liu YJ,. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161.
61. Moser M, Murphy KM,. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1: 199-205.
62. Bharadwaj AS, Bewtra AK, Agrawal DK,. Dendritic cells in allergic airway inflammation. Can J Physiol Pharmacol 2007; 85: 686-699.
63. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, et al. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol 2005; 175: 6265-6270.
64. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182: 2816-2826.
65. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM,. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol 2008; 180: 4836-4847.
66. Shao Z, Bharadwaj AS, McGee HS, Makinde TO, Agrawal DK,. Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation. J Allergy Clin Immunol 2009; 123: 917 e2-924 e2.
67. Kool M, van Nimwegen M, Willart MA, Muskens F, Boon L, Smit JJ, et al. An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation. J Immunol 2009; 183: 1074-1082.
68. Bochner BS, Busse WW,. Allergy and asthma. J Allergy Clin Immunol 2005; 115: 953-959.
69. Robinson DS, Larche M, Durham SR,. Tregs and allergic disease. J Clin Invest 2004; 114: 1389-1397.
70. Akdis M, Blaser K, Akdis CA,. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-968; quiz 969.
71. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ,. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105: 9331-9336.
72. McGee HS, Yagita H, Shao Z, Agrawal DK,. PD-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma. Am J Respir Cell Mol Biol 2010; in press.
73. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643.
74. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181: 6738-6746.
75. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L,. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004; 20: 327-336.
76. Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003; 197: 1721-1730.
77. Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med 2003; 198: 31-38.
78. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ,. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
79. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL,. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173: 945-954.
80. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH,. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006; 203: 2223-2227.
81. Grakoui A, John Wherry E, Hanson HL, Walker C, Ahmed R,. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol 2006; 45: 468-472.
82. Fukushima A, Yamaguchi T, Azuma M, Yagita H, Ueno H,. Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br J Ophthalmol 2006; 90: 1040-1045.
83. Ritprajak P, Hashiguchi M, Tsushima F, Chalermsarp N, Azuma M,. Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8(+) T cell responses. J Immunol 2010; 184: 4918-4925.
84. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 1757-1761.